NeuroMetrix Inc., a Waltham company whose product portfolio includes diagnostics for diabetes, announced the marketing launch of one of its products in Japan.
The product is called NC-stat DPNCheck, and it is designed to detect diabetic peripheral neuropathy, or DPN, at an early stage. DPN is the most common complication of diabetes, affecting more than half the diabetes population, the company’s press release noted. Diabetes is a major health issue in Japan affecting nearly 8 percent of the population, or about 7 million people.
Omron Healthcare, a company based in Kyoto, Japan, that specializes in health care monitoring, is NeuroMetrix’s exclusive distributor for Japan and other Asian markets. Omron is currently guiding DPNCheck through the Japan regulatory process which is expected to conclude during this quarter, NeuroMetrix said.
The annual meeting of the Japan Diabetes Society is scheduled to run from Thursday through Saturday. The plan is to use this event to unveil a product awareness campaign for the DPNCheck, the company said.
According to the NeuroMetrix website, the company’s product portfolio includes “wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances.”
The company was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996 by Shai Gozani, MD, NeuroMetrix’s president and chief executive.
Chris Reidy can be reached at email@example.com.